Why in news?
Recent scientific studies have identified antibodies that target the Envelope Dimer Epitope (EDE) of the dengue virus and can neutralise all four serotypes. Researchers hope that vaccines designed to elicit EDE antibodies will offer broad protection against dengue.
Understanding the dengue virus
Dengue is a mosquito‑borne disease caused by four closely related viruses. Traditional vaccines face challenges because antibodies against one serotype can sometimes enhance infection by another, a phenomenon called antibody‑dependent enhancement.
What is the EDE?
- Structural feature: The dengue virus envelope protein exists as pairs (dimers) on the viral surface. At the interface of each pair lies the Envelope Dimer Epitope – a cluster of amino acids formed by both proteins.
- Cross‑neutralisation: Antibodies that recognise this quaternary epitope latch onto the dimer and block the structural changes the virus needs to enter human cells. They have been shown to neutralise all four dengue serotypes and even the related Zika virus.
- Vaccine implication: Vaccines that stimulate EDE‑specific antibodies could provide broad and durable protection without triggering harmful immune responses.
Why it matters
Dengue causes millions of infections and thousands of deaths annually, particularly in tropical countries. A vaccine based on EDE could overcome current limitations and become a game‑changer for public health. Continued research is needed to ensure safety and effectiveness across diverse populations.
